Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer.

被引：0
|
作者：
Houede, Nadine
Roubaud, Guilhem
Mahammedi, Hakim
Vedrine, Lionel
Joly, Florence
Mourey, Loic
Pfister, Christian
Culine, Stephane
Goberna, Alejandro
Lortal, Barbara
Pulido, Marina
Pourquier, Philippe
Bellera, Carine A.
机构：
[1] Ctr Hosp Reg Univ, Nimes, France
[2] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[3] Ctr Jean Perrin, Clermont Ferrand, France
[4] Val de Grace Hosp, Paris, France
[5] Ctr Francois Baclesse, Comite Urogynecol, F-14021 Caen, France
[6] Inst Claudius Regaud, Toulouse, France
[7] Ctr Hosp Rouen, Rouen, France
[8] Hop St Louis, Dept Med Oncol, Paris, France
[9] Inst Bergonie, Bordeaux, France
[10] INSERM, U916, Bordeaux, France
[11] Reg Comprehens Canc Ctr, Inst Bergonie, Bordeaux, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.304
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
304
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and prognostic factor analysis in second-line chemotherapy for elderly patients with metastatic gastric cancer.
    Shoji, Ayaka
    Hasegawa, Hiroko
    Kato, Seiya
    Kiyota, Ryosuke
    Shinkai, Kazuma
    Tashiro, Taku
    Ishihara, Akio
    Iwasaki, Tetsuya
    Tanaka, Satoshi
    Akasaka, Tomofumi
    Sakakibara, Yuko
    Nakazuru, Shoichi
    Ishida, Hisashi
    Hirao, Motohiro
    Mita, Eiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice
    Flannery, K.
    Black-Shinn, J.
    Boyd, M.
    Robert, N.
    Kamat, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [23] Safety and efficacy of lenvatinib in HCC beyond second-line treatment.
    Jefremow, Andre
    Wiesmueller, Marco
    Rouse, Rachel Amande
    Dietrich, Peter
    Kremer, Andreas Emanuel
    Waldner, Maximilian Josef
    Neurath, Markus Friedrich
    Siebler, Jurgen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase II trial of temsirolimus in second-line metastatic urothelial cancer
    Gerullis, H.
    Eimer, C.
    Ecke, T. H.
    Georgas, E.
    Freitas, C.
    Kastenholz, S.
    Arndt, C.
    Heusch, C.
    Otto, T.
    [J]. MEDICAL ONCOLOGY, 2012, 29 (04) : 2870 - 2876
  • [25] Oxaliplatin in the second-line treatment of fluorouracil-resistant colorectal cancer.
    Wilson, G
    Papamichael, P
    Dent, JT
    Richards, F
    Slevin, ML
    Seymour, MT
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 : 29 - 29
  • [26] Nab-paclitaxel as second-line treatment in advanced biliary cancer.
    Prager, Gerald W.
    Kornek, Gabriela
    Scheithauer, Werner
    Steger, Guenther G.
    Zielinski, Christoph
    Unseld, Matthias
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [27] A phase II trial of temsirolimus in second-line metastatic urothelial cancer
    H. Gerullis
    C. Eimer
    T. H. Ecke
    E. Georgas
    C. Freitas
    S. Kastenholz
    C. Arndt
    C. Heusch
    T. Otto
    [J]. Medical Oncology, 2012, 29 : 2870 - 2876
  • [28] Second-line chemotherapy in advanced bladder cancer
    Pavone-Macaluso, M
    Sternberg, C
    [J]. UROLOGIA INTERNATIONALIS, 2000, 64 (02) : 61 - 69
  • [29] Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
    Bourlon, Maria T.
    Velazquez, Hugo E.
    Luna-Santiago, Rodrigo
    Vazquez-Manjarrez, Sara
    Bourlon, Christianne
    [J]. ONCOLOGY-NEW YORK, 2018, 32 (02): : 64 - 68
  • [30] Second-line therapy of metastatic bladder cancer
    Retz, M.
    Bokemeyer, C.
    [J]. ONKOLOGE, 2012, 18 (11): : 1018 - 1022
12345